237 related articles for article (PubMed ID: 12710291)
21. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
[TBL] [Abstract][Full Text] [Related]
22. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
Fisher M; Folland E
Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
[TBL] [Abstract][Full Text] [Related]
23. Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease.
Al-Omran M
Vasc Health Risk Manag; 2007; 3(6):1019-27. PubMed ID: 18200820
[TBL] [Abstract][Full Text] [Related]
24. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease.
Hussain MA; Al-Omran M; Mamdani M; Eisenberg N; Premji A; Saldanha L; Wang X; Verma S; Lindsay TF
JAMA Surg; 2016 Aug; 151(8):742-50. PubMed ID: 27050566
[TBL] [Abstract][Full Text] [Related]
26. [Prevalence and management of patients with a prior history of atherothrombotic disease in primary care in France. Results of the ECLAT1 survey].
Bóngard V; Cambou JP; Coppe G; Jullien G; Vahanian A; Mas JL
Arch Mal Coeur Vaiss; 2003 Sep; 96(9):833-40. PubMed ID: 14571635
[TBL] [Abstract][Full Text] [Related]
27. Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Kundhal KK; Chin SL; Harrison L; Nowacki B; Doobay B; Titley J; Ciná C; Anand SS
Can J Cardiol; 2007 Apr; 23(5):357-61. PubMed ID: 17440640
[TBL] [Abstract][Full Text] [Related]
28. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications.
Béjot Y; Zeller M; Lorgis L; Troisgros O; Aboa-Eboulé C; Osseby GV; Giroud M; Cottin Y
J Neurol Neurosurg Psychiatry; 2013 Mar; 84(3):348-53. PubMed ID: 23152636
[TBL] [Abstract][Full Text] [Related]
29. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
30. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
[TBL] [Abstract][Full Text] [Related]
31. National survey on prescription of cardiovascular drugs among outpatients with coronary artery disease in Switzerland.
Muntwyler J; Noseda G; Darioli R; Gruner C; Gutzwiller F; Follath F
Swiss Med Wkly; 2003 Feb; 133(5-6):88-92. PubMed ID: 12644962
[TBL] [Abstract][Full Text] [Related]
32. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC
Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570
[TBL] [Abstract][Full Text] [Related]
33. REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year.
Sabouret P; Cacoub P; Dallongeville J; Krempf M; Mas JL; Pinel JF; Priollet P; Steg G; Taminau D; Montalescot G;
Arch Cardiovasc Dis; 2008 Feb; 101(2):81-8. PubMed ID: 18398391
[TBL] [Abstract][Full Text] [Related]
34. [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Danchin N; Hanania G; Grenier O; Vaur L; Amelineau E; Guéret P; Blanchard D; Ferrières J; Genès N; Lablanche JM; Cantet C; Cambou JP
Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):1-6. PubMed ID: 12710288
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry).
Puymirat E; Aissaoui N; Lemesle G; Cottin Y; Coste P; Schiele F; Ferrières J; Simon T; Danchin N;
Am J Cardiol; 2017 Mar; 119(5):692-697. PubMed ID: 28038725
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.
Sharma KK; Mathur M; Gupta R; Guptha S; Roy S; Khedar RS; Gupta N; Gupta R
Indian Heart J; 2013; 65(3):250-5. PubMed ID: 23809376
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
38. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Barron HV; Michaels AD; Maynard C; Every NR
J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
[TBL] [Abstract][Full Text] [Related]
39. Repeat prescriptions of guideline-based secondary prevention medication in patients with type 2 diabetes and previous myocardial infarction in Dutch primary care.
Kasteleyn MJ; Wezendonk A; Vos RC; Numans ME; Jansen H; Rutten GE
Fam Pract; 2014 Dec; 31(6):688-93. PubMed ID: 25106412
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry.
Khan S; Flather M; Mister R; Delahunty N; Fowkes G; Bradbury A; Stansby G
Eur J Vasc Endovasc Surg; 2007 Apr; 33(4):442-50. PubMed ID: 17196851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
